Trial · NCT05515978
Pragmatic Trial of Metformin for Glucose Intolerance or Increased BMI in Prostate Cancer Patients
NCT05515978, Early phase 1, Active not recruiting, University of Colorado, Denver
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Pragmatic Trial of Metformin for Glucose Intolerance or Increased BMI in Prostate Cancer Patients. Trials, record NCT05515978. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05515978
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pragmatic Trial of Metformin for Glucose Intolerance or Increased BMI in Prostate Cancer Patients
- NCT number
- NCT05515978
- Status
- Active not recruiting
- Phases
- Early phase 1
- Enrollment
- 100 participants, estimated
- Lead sponsor
- University of Colorado, Denver
- Conditions
- Prostate Cancer
- Interventions
- Metformin, Lifestyle Modification
- First posted
- 2022-08-25
- Last updated
- 2026-10-26
Source ClinicalTrials.gov
Registered outcomes27
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Successful accrual of 100 patients to the pragmatic trial in the first four years | 4 years | Once there are 6 months of follow-up data on the first 100 patients, a formal analysis will be done to determine the completeness of data and the potential for a powered study. Outcome measure was amended January 2025. |
| Secondary | Effectiveness: 1a: To determine the effectiveness of metformin prescribed in a pragmatic trial on Body Mass Index | 2 years | Metabolic response. Key metabolic parameters assessed as part of routine care: Body Mass Index (BMI) |
| Secondary | Effectiveness: 1a: To determine the effectiveness of metformin prescribed in a pragmatic trial on Weight | 2 years | Metabolic response. Key metabolic parameter assessed as part of routine care: Weight |
| Secondary | Effectiveness: 1a: To determine the effectiveness of metformin prescribed in a pragmatic trial on HbA1C | 2 years | Metabolic response. Key metabolic parameters assessed as part of routine care: HbA1C |
| Secondary | Effectiveness: 1a: To determine the effectiveness of metformin prescribed in a pragmatic trial on Blood Pressure | 2 years | Metabolic response. Key metabolic parameters assessed as part of routine care: blood pressure |
| Secondary | Effectiveness: 1a: To determine the effectiveness of metformin prescribed in a pragmatic trial on Glucose Levels | 2 years | Metabolic response. Key metabolic parameters assessed as part of routine care: random glucose level. |
| Secondary | Effectiveness: 1a: To determine the effectiveness of metformin prescribed in a pragmatic trial on key physiologic parameters - BMI | 2 years | Metabolic response. Key metabolic parameter assessed as part of routine care: Body Mass Index (BMI) |
| Secondary | Effectiveness: 1a: To determine the effectiveness of metformin prescribed in a pragmatic trial on key physiologic parameters - Weight | 2 years | Metabolic response. Key metabolic parameters assessed as part of routine care: Weight |
| Secondary | Effectiveness: 1a: To determine the effectiveness of metformin prescribed in a pragmatic trial on key physiologic parameters - HbA1C | 2 years | Metabolic response. Key metabolic parameters assessed as part of routine care: HbA1C |
| Secondary | Effectiveness: 1a: To determine the effectiveness of metformin prescribed in a pragmatic trial on key physiologic parameters - blood pressure | 2 years | Metabolic response. Key metabolic parameters assessed as part of routine care: blood pressure |
1 to 10 of 27Source ClinicalTrials.gov
See all 27 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05515978
GET https://conductscience.org/api/trials/v1/NCT05515978/registered?page=2